Truist Securities Upgrades Sutro Biopharma to 'Buy'

Truist Securities has upgraded Sutro Biopharma, Inc. (NasdaqGM: STRO) to a 'buy' rating, setting a price target of $50. This move by analyst Supawat Thongthip on June 11, 2026, reflects confidence in the biotechnology company's future prospects. Shares of Sutro Biopharma are currently trading at $26.35.

What Changed in Truist Securities' Sutro Biopharma Position

Truist Securities' upgrade to a 'buy' rating with a $50 price target indicates a positive outlook on Sutro Biopharma's potential. The firm's action suggests that it sees upside potential in the company's stock, which is trading well below the new target.

Other Institutional Activity in Sutro Biopharma

Several institutional investors have been active in Sutro Biopharma. BVF Inc/IL initiated a position with 1,251,788 shares worth approximately $31.2 million. Affinity Asset Advisors, LLC increased its holdings by 321,137 shares to a total of 1,069,519 shares valued at about $26.6 million. Samsara Biocapital, LLC significantly boosted its stake by 858,369 shares, resulting in 1,062,872 shares worth roughly $26.5 million. Kynam Capital Management, LP also increased its position by 392,968 shares, ending with 872,558 shares valued at $21.7 million. OrbiMed Advisors LLC and Vanguard Capital Management LLC both initiated positions with 801,144 and 720,442 shares, respectively.

Sutro Biopharma, Inc. Stock Up 47.7%

Shares of Sutro Biopharma, Inc. (NasdaqGM: STRO) are trading near $26.35. The company has a market capitalization of approximately $477.2 million. Although it has a negative forward P/E ratio of -4.18, indicating it's not currently profitable, the stock has shown volatility with a 52-week range between $6.70 and $43.85. It has a 50-day moving average of $31.49 and a 200-day moving average of $17.64. Sutro Biopharma maintains a healthy current ratio of 3.12 and a quick ratio of 3.04, reflecting strong liquidity.

Recent Earnings

Sutro Biopharma reported revenue of $99.6 million, though it experienced a revenue decline of 16.5%. The company's net margin stands at -154.2%, highlighting significant losses. With earnings per share at -$16.35, Sutro Biopharma is not currently profitable. The next earnings report is expected on August 11, 2025.

Insider Buying and Selling at Sutro Biopharma, Inc.

Recently, several insiders at Sutro Biopharma made significant purchases. On June 5, 2026, insiders including Jon Marc Wigginton, Michael Dybbs, Daniel Petree, Sukhi Jagpal, James Panek, and Heidi Hunter each bought 10,000 shares. These transactions were not part of a pre-planned trading program.

Analysts Set New Price Targets

On June 11, 2026, Truist Securities assumed coverage with a 'buy' rating and a $50 price target. Barclays initiated coverage on May 28, 2026, also with a 'buy' rating and a target of $56. On May 15, 2026, both Leerink Partners and HC Wainwright & Co. maintained 'buy' ratings with price targets of $43 and $50, respectively. Wedbush upgraded the stock to 'buy' with a $60 target on the same day. The consensus among 13 analysts is a 'strong buy', with an average price target of $48.31.

About Sutro Biopharma

Sutro Biopharma, Inc. is a biotechnology company based in South San Francisco, California. It focuses on developing oncology therapies, particularly antibody drug conjugates (ADCs) using its proprietary XpressCF and XpressCF+ platforms. Sutro's lead product candidate, STRO-004, targets tissue factor-expressing solid tumors. The company is also advancing vaccine candidates and other ADCs in collaboration with partners like Vaxcyte and Astellas Pharma. Led by CEO Jane Chung, Sutro employs 133 people.

Bottom Line

Truist Securities' upgrade of Sutro Biopharma to a 'buy' reflects optimism about the company's future. Despite recent losses, Sutro's innovative drug pipeline and strategic partnerships position it for potential growth. Investors should note that analyst ratings and price targets are forward-looking and subject to change as new information becomes available.